Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of December 21st – 27th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. Here’s the Dividend Pot Stock Most Likely to Double in 2021

IIPR More Than Doubled So Far This Year and is in a Strong Position for a Repeat Performance

Dividend stocks aren’t generally known for generating tremendous gains over short periods. Given enough time, dividend stocks can make investors a lot of money. There are some dividend stocks, however, that are more hares than tortoises. They pay attractive dividends and deliver impressive growth at the same time. One such stock especially stands out, in my opinion. I think that the dividend stock most likely to double in 2021 is… Innovative Industrial Properties (NYSE: IIPR) (FRA: 1IK).

READ FULL IIPR ARTICLE

9. Is Compass Pathways Stock a Buy?

This Small-Cap Biotech May Very Well Revolutionize How We Treat Depression

Despite having an IPO just three months ago, Compass Pathways (NASDAQ: CMPS) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering, that investment would be worth over $32,400 today, far outperforming the S&P 500’s 11.3% gain during the same period. Despite being a small fish in the biotech ocean, Compass Pathways has the backing of Silicon Valley billionaire tech-investor Peter Thiel with a 10 million euro stake. Just what could spark so much interest in an early-stage company with only one pipeline candidate?

READ FULL CMPS ARTICLE

8. Paradigm Initiates Coverage on Trulieve With $59 Price Target

Corey Hammill, Paradigm Senior Analyst Headlined the Initiation Note With “Flourishing in Florida & Looking Beyond”

Earlier this month, Paradigm Capital initiated coverage on Trulieve (CSE: TRUL) (OTCQX: TCNNF)  with a C$59 12-month price target and a Speculative buy rating. Trulieve currently has 14 analysts covering the company with a weighted 12-month price target of C$53.75. This is up from the average at the start of the month, which was C$43.60. Two analysts have “STRONG BUY” ratings, while the remaining 12 have “BUY” ratings.

READ FULL TRULIEVE ARTICLE

7. New Psychedelic Stock Novamind Receives CSE Conditional Listing Approval

Subject to Final Exchange Approval, the Common Shares of Novamind Are Expected to Commence Trading on the CSE Under the Ticker Symbol “NM” on or About January 5, 2021

Novamind (CSE: NM), formerly Hinterland …

Full story available on Benzinga.com

More Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week